Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 23Gastrointestinal 7CNS 3Plasma cell 2Lymphoid 2Head & Neck 2Gynecologic 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Solid Tumors 1

Interventions

pembrolizumab 15Injections 13Pemetrexed 8Carboplatin 8tislelizumab 6Interviews as Topic 6Standard of Care 5Specimen Handling 5Practice Guidelines as Topic 5Fluorouracil 5Cisplatin 5Bevacizumab 5atezolizumab 4Oxaliplatin 4Docetaxel 4sotorasib 3fludarabine 3Paclitaxel 3Nivolumab 3Methods 3Leucovorin 3Irinotecan 3Educational Status 3Early Intervention, Educational 3Capecitabine 3toripalimab 2Radiotherapy, Intensity-Modulated 2Patient Navigation 2Magnetic Resonance Spectroscopy 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Trastuzumab × Other solid neoplasm × 30 days × Clear all
NCT02320435 2026-05-12

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Hoffmann-La Roche

Phase 3 Active not recruiting
154 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡